Once-daily oral brepocitinib 30 mg shows improvement in measures of skin and muscle disease in patients with dermatomyositis, compared with placebo, according to findings from a phase 3 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback